Postmenopausal hormone use for cardioprotection: What we know and what we must learn

Current Opinion in Cardiology

Volumn 14, Issue 4, 1999, Pages 292-297

  Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; UNITED STATES;

EID: 0032812371     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199907000-00003     Document Type: Review

References (23)

1. 1 Wenger NK: Coronary heart disease in women: an older woman's major health risk. BMJ 1997, 315:1085-1090.
2. 2 Abu-Halawa SA, Thompson K, Kirkeeide RL, Vaughn WK, Rosales O, Fujisi K, et al.: Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am J Cardiol 1998, 82:409-413. The results of this study reveal decreased fatal and nonfatal myocardial infarction and total mortality in estrogen users versus nonusers after percutaneous transluminal coronary angioplasty. No difference in the rate of restenosis is noted.
3. 3 Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-1037.
4. 4 Barrett-Connor E, Grady D: Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998, 19:55-72. This meta-analysis of observational studies of HRT shows the cardiovascular benefits of this therapy are comparable to estrogen.
5. 5 Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford C, McGowan JA: The evolution of the Women's Health Initiative: perspective from the NIH. JAMA 1995, 50:50-55.
6. 6 Vickers MR, Meade TW, Wilkes HC: Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Ciba Found Symp 1995, 191:150-164.
7. 7 The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199-208.
8. 8 Guetta V, Cannon RO III: Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996, 93:1928-1937.
9. 9 Sbarouni E, Kyriakides ZS, Kremastinos DT: The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998, 32:1244-1250. Additive and differing effects of simvastatin and HRT are evident in this study.
10. 10 Hoogerbrugge N, Zillikens MC, Jansen H, Meeter K, Deckers JW, Birkenhäger JC: Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease. Metabolism 1998, 47:675-680. In this study, estrogen is found to favorably affect dyslipidemia and may have antioxidant effects especially in nonsmoking women.
11. 11 Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, et al.: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995, 91:1952-1958.
12. 12 Chen F-P, Lee N, Wang C-H, Cherng W-J, Soong Y-K: Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998, 69:267-273. The results of this study show that HRT favorably affects coronary risk factors.
13. 13 Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, et al.: 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995, 92:24-30.
14. 14 Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, et al.: Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998, 98:1158-1163. According to this study, micronized progesterone does not attenuate estradiol benefit on endothelium-dependent vasodilation.
15. 15 Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, et al.: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999, 99:354-360. This study reveals that estrogen may benefit the vasculature of hypercholesterolemic women, even those receiving statin therapy.
16. 16 Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89:52-60.
17. 17 Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P: Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993, 342:133-136.
18. 18 Al-Khalili F, Landgren B-M, Eksborg S, Franco-Cereceda A, Schenck-Gustafsson K: Does sublingual 17β-oestradiol have any effects on exercise capacity and myocardial ischaemia in post-menopausal women with stable coronary artery disease? Eur Heart J 1998, 19:1019-1026. No effect of acute estradiol on exercise capacity or exercise ischemia is evident in this study.
19. 19 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605-613. In this clinical trial, oral CEE and MPA did not reduce overall CHD events in postmenopausal women with CHD.
20. 20 Brett KM, Madans JH: Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997, 145:536-545.
21. 21 Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ: Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999, 130:545-553. Sociodemographic factors are shown in this study to be more associated with HRT use than clinical risk factors.
22. 22 Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279:1445-1451. This study reveals that raloxifene favorably alters biochemical markers of cardiovascular risk.
23. 23 Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M, et al.: Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. J Womens Health 1998, 7:839-847. This is a review of hormones and selective estrogen receptor modulators and their potential roles in cardiovascular protection and postmenopausal women's health.